Olema Pharmaceuticals (OLMA) Cash from Investing Activities (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Cash from Investing Activities data on record, last reported at $4.5 million in Q1 2026.

  • On a quarterly basis, Cash from Investing Activities rose 110.05% to $4.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$106.1 million, a 10.4% increase, with the full-year FY2025 number at -$155.8 million, down 66.54% from a year prior.
  • Cash from Investing Activities reached $4.5 million in Q1 2026 per OLMA's latest filing, up from -$162.2 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for OLMA hit a ceiling of $45.9 million in Q3 2024 and a floor of -$162.2 million in Q4 2025.
  • A 5-year average of -$9.3 million and a median of $14.1 million in 2023 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: tumbled 289.24% in 2023, then soared 801.8% in 2025.
  • Tracing OLMA's Cash from Investing Activities over 5 years: stood at $16.3 million in 2022, then crashed by 289.24% to -$30.9 million in 2023, then plummeted by 270.12% to -$114.4 million in 2024, then crashed by 41.74% to -$162.2 million in 2025, then surged by 102.79% to $4.5 million in 2026.
  • Business Quant data shows Cash from Investing Activities for OLMA at $4.5 million in Q1 2026, -$162.2 million in Q4 2025, and $17.3 million in Q3 2025.